News

A regimen of docetaxel and cisplatin offers better survival and response rates than a combination of vinorelbine and cisplatin in the treatment of advanced non-small-cell lung cancer, according to a phase 3 study published in the online version of the Journal of Clinical Oncology. In addition, the findings demonstrated that docetaxel is as effective as vinorelbine/cisplatin when combined with another platinum, carboplatin.

The clinical benefit of aspirin on first myocardial infarction diminishes with regular-but not intermittent-use of nonsteroidal anti-inflammatory drugs, according to a study published in the journal Circulation.

New Orleans-The results of the Antihypertensive and Lipid-Lowering Treatmentto Prevent Heart Attack (ALLHAT) Trial, along with the highlights of theSeventh Report of the Joint National Committee on Prevention, Detection,Evaluation, and Treatment of High Blood Pressure (JNC 7), were reviewedat an educational session of the recently concluded 38th ASHP Midyear ClinicalMeeting.

The American Heart Association (AHA) Scientific Sessions comprise the largest meeting of its kind held in the cardiovascular field, with several thousand presentations given each year. The recently concluded 2003 AHA Scientific Sessions included presentations of trials that evaluated potential therapeutic compounds, as well as widely used and accepted compounds in new dosages or combinations, for the treatment of cardiovascular disorders. The compilation of clinical news reviewed focuses on the cardiovascular pharmacotherapy trials of greatest interest to formulary decision-makers, including: VALIANT, REVERSAL, SPORTIF V, PAPABEAR, PRIMO-CABG, and CREST.

SBM combines prevention and wellness strategies for improved outcomes and cost savings

health risks are not the only drawback for overweight kids ... take my word for it!

MCOs should word arbitration clauses as carefully as the rest of the contract

DM plays a key role in the evolution of specialty pharmacy

Developing preferred relationships with members leads to increased market share for payers

What do you do when you have exhausted all options for improving performance in an environment that is determined to protect the status quo? What do you do when your organization has reached the presumed limit of potential performance and has grown all too comfortable with its market lead?

An insightful man named Blake Segal once said, "It is not a parent's job to protect their kids from life, but to prepare them for it." Wise words indeed, and ones that Bob Greczyn has taken to heart. Although he has three children of his own, he wants to help prepare yours for a healthy future, and everyone else's as well.

Our recent "ER is a Hit With Insured Americans" news item stirred up some reader response.

Bethesda, Md.-The daily activities of health-system pharmacists are greatlyaffected by the Health Insurance Portability and Accountability Act of 1996(HIPAA). To help keep practitioners up-to-date with current regulationsand other important information, ASHP has developed an online resource centeron its website, www.ashp.org.

James E. Orlikoff (pictured at right), an expert in health-care governance,organizational development, and leadership quality, will be the keynotespeaker during the meeting's Opening General Session that takes place from9 a.m. to 11 p.m. on Monday, Dec. 8, in Hall D. He is president of Orlikoffand Associates, Inc., a consulting firm specializing in health-care governanceand leadership quality, organizational development, strategy, and risk management.He is the National Advisor on Governance and Leadership to the AmericanHospital Association and Health Forum.

An intravenous formulation of lansoprazole has been developed and is under review by FDA. If approved, lansoprazole will be the second IV proton pump inhibitor available in the United States, providing an alternative to the currently available pantoprazole IV. The pharmacokinetic and pharmacodynamic properties of lansoprazole IV have been found to be comparable to the oral form. Until more data are available the agent, if approved, should be reserved as an option for patients unable to take lansoprazole via the oral route.

Atazanavir is a novel azapeptide protease inhibitor (PI) that has been approved by FDA for use in combination with other antiretroviral agents in treatment-naïve and treatment-experienced HIV-infected individuals. Atazanavir has a low pill burden consisting of 2 capsules administered once daily and it has an adverse effect profile that is not associated with clinically relevant lipid effects. In clinical studies of up to 48 weeks, atazanavir demonstrated comparable antiretroviral efficacy to nelfinavir and efavirenz in treatment-naïve patients. The most common adverse effect associated with atazanavir is a reversible dose-related increase in unconjugated (indirect) bilirubin.

State governments and enforcement agencies have become more active in efforts to regulate drug sales and marketing and have addressed a number of pressing issues:

Proponents say specialty facilities provide better care with less cost, while others disagree.

Provider acceptance, administrative hassles, program design remain the important challenges

Department of Labor files suit against a fraudulent plan

CIGNA and Aetna both involved in ERISA cases

Outcome of ERISA interpretation will affect care management programs including drug utilization review

Healthcare today is about choices

Two mergers might put a new spin on the PBM market

It only takes two clicks to vote for the thought leader who provided you with the most insight in 2003

New molecular entities and new formulations, FDA actions and generic approvals

Source: Atlantic Information Services, Drug Cost Management Report

Bea Leopold knows only too well how traumatic and potentially life-altering genetic testing can be. Having a sister with ovarian cancer and a mother who died of breast cancer convinced Leopold to be tested three-and-a-half years ago for the BRCA gene, which is predictive of both kinds of cancer.